Imatinib

Generic Name: Imatinib

Brand Names: Gleevec, Glivec, Imatinib Teva, Imatinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₁N_₇O

CAS Number: 152459-95-5

Unique Ingredient Identifier: BKJ8M8G5HI

Background: Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ...

Indication: Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferativ...

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor

Associated Therapies: -

Clinical Trials

Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL

Phase 1

Terminated

Conditions: ALK+ Anaplastic Large Cell Lymphoma

Interventions: Drug: Brentuximab vedotin
Drug: Imatinib

First Posted Date: 2015-06-04

Last Posted Date: 2022-03-03

Lead Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie

Target Recruit Count: 3

Registration Number: NCT02462538

Locations: 🇦🇹
Universitätsklinik f. Innere Medizin I, AKH Wien, Klinische Abteilung für Hämatologie und Hämostaseologie, Wien, Austria

Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy

Phase 2

Conditions: Advanced, Refractory Cancer

Interventions: Drug: Imatinib

First Posted Date: 2015-06-03

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 14

Registration Number: NCT02461849

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST

Phase 3

Active, not recruiting

Conditions: Sarcoma

Interventions: Drug: Imatinib

First Posted Date: 2015-04-10

Last Posted Date: 2023-11-09

Lead Sponsor: Heikki Joensuu

Target Recruit Count: 255

Registration Number: NCT02413736

Locations: 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland

A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)

Phase 2

Active, not recruiting

Conditions: Gastrointestinal Stromal Tumour

Interventions: Drug: imatinib
Drug: Regorafenib

First Posted Date: 2015-02-19

Last Posted Date: 2023-07-07

Lead Sponsor: Australasian Gastro-Intestinal Trials Group

Target Recruit Count: 78

Registration Number: NCT02365441

Locations: 🇦🇺
Prince of Wales Hospital, Sydney, New South Wales, Australia
🇦🇺
Flinders Medical Centre, Adelaide, South Australia, Australia
🇦🇺
Sir Charles Gairdner, Perth, Western Australia, Australia

and more 22 locations

Treatment of Cervical Spinal Cord Injury With Imatinib - a Safety and Feasibility Study

Phase 2

Conditions: Cervical Spinal Cord Injury

Interventions: Drug: Imatinib

First Posted Date: 2015-02-16

Last Posted Date: 2018-03-07

Lead Sponsor: Professor Mikael Svensson, MD PhD

Target Recruit Count: 10

Registration Number: NCT02363361

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Phase 1

Completed

Conditions: Hematologic Malignancy

Interventions: Drug: BBI608
Drug: Dexamethasone
Drug: Bortezomib
Drug: Imatinib
Drug: Ibrutinib

First Posted Date: 2015-02-02

Last Posted Date: 2023-11-14

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 15

Registration Number: NCT02352558

Locations: 🇺🇸
Virginia Oncology Associates, Norfolk, Virginia, United States
🇺🇸
West Clinic, Germantown, Tennessee, United States
🇺🇸
Northwest Cancer Specialists, PC, Vancouver, Washington, United States

and more 5 locations

Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

Phase 3

Completed

Conditions: Leukemia, Chronic Myeloid

Interventions: Drug: imatinib
Drug: nilotinib
Drug: dasatinib

First Posted Date: 2014-12-29

Last Posted Date: 2024-08-13

Lead Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Target Recruit Count: 229

Registration Number: NCT02326311

Locations: 🇮🇹
Policlinico Universitario di Milano, Milano, Italy

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

Phase 4

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Imatinib

First Posted Date: 2014-12-15

Last Posted Date: 2014-12-15

Lead Sponsor: Cttq

Target Recruit Count: 90

Registration Number: NCT02317159

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

Phase 3

Completed

Conditions: Leukemia

Interventions: Drug: Imatinib
Drug: Nilotinib

First Posted Date: 2014-10-23

Last Posted Date: 2019-08-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 225

Registration Number: NCT02272777

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years

Phase 3

Terminated

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Nilotinib
Drug: Imatinib

First Posted Date: 2014-06-25

Last Posted Date: 2019-12-02

Lead Sponsor: Prof. Dr. Nikolas von Bubnoff

Target Recruit Count: 14

Registration Number: NCT02174445

Locations: 🇩🇪
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
🇩🇪
Universitätsklinikum Aachen, Aachen, Germany
🇩🇪
Praxis Dr. Hauch, Erfurt, Germany

and more 15 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy